Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer

Figure 4

Heterotopic model for pancreatic cancer. (a) Average tumor volume of Luc-H19 group (𝑛=8) and DTA-H19 group (𝑛=7) during the experiment using CRL-1469 cells. Treatments were administrated on days 0, 3, and 6 by direct intratumoral injection after subcutaneous implantation of human pancreatic carcinoma cells in the back of nude mice. Three days after the last treatment, the animals were sacrificed. (b) Average of ex vivo tumor volume at the end of the experiment, tumors generated using CRL-1469 cells. (c) Tumor Growth Progression of Luc-H19 (𝑛=5) and DTA-H19 (𝑛=5) groups, in experiment using CRL-2547 cell line.

(a)

(b)

(c)